文献速递心外重症与机械循环支持

体外膜氧合合并多器官衰竭:分子吸附再循环系统治疗能否改善生存?

Extracorporeal membrane oxygenation with multiple-organ failure: Can molecular adsorbent recirculating system therapy improve survival?
PubMed 文献 · J Heart Lung Transplant · 2016-10-07

该回顾性研究纳入2010至2015年接受ECMO且符合急性肝衰竭标准的28例患者,其中14例接受MARS治疗,14例仅接受最佳药物治疗。MARS组肝功能指标显著改善,成功脱离ECMO生存率为64%对21%(p=0.02),且无MARS相关并发症。

要点

  • MARS治疗可加速ECMO合并急性肝衰竭患者的肝功能恢复。
  • MARS组脱离ECMO生存率显著高于对照组(64% vs 21%,p=0.02)。
  • MARS治疗未增加相关并发症。

核心结论

  • MARS治疗在ECMO患者中安全加速肝功能恢复并提高脱离ECMO的生存率,且不增加并发症。

研究设计与样本

  • 回顾性图表分析,纳入2010至2015年接受ECMO且符合急性肝衰竭标准的28例患者,其中14例接受MARS治疗(M组),14例接受最佳药物治疗(C组)。

主要发现

  • 两组人口学、临床危险因素及ECMO前实验室数据无差异。
  • M组MARS连续使用8天±9天,总胆红素、丙氨酸氨基转移酶和国际标准化比值显著改善。
  • M组脱离ECMO生存率为64%(9/14),C组为21%(3/14),p=0.02。
  • ECMO期间肝功能恶化相关死亡率M组为40%(2/5例死亡),C组为100%(11/11例死亡),p=0.004。
  • ECMO后30天生存率M组为43%(6/14),C组为14%(2/14),p=0.09。

关键数值与推荐

  • 急性肝衰竭诊断标准为高胆红素血症(总胆红素≥10 mg/dl)或转氨酶升高(丙氨酸氨基转移酶>1,000 IU/L)。

临床怎么用

  • 对于ECMO合并急性肝衰竭的患者,可考虑使用MARS治疗以改善肝功能并提高脱离ECMO的成功率。

局限性

  • 回顾性研究,样本量较小(28例),非随机分组,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver dialysis, molecular adsorbent recirculating system (MARS) particularly, has been used in liver failure to bridge to transplantation. We expanded the indication for MARS to patients with acute shock liver failure and cardiopulmonary failure on extracorporeal membrane oxygenation (ECMO), aiming to improve survival to wean from ECMO. METHODS: Retrospective chart analysis of patients on ECMO between 2010 and 2015 found 28 patients who met the criteria for acute liver failure, diagnosed by hyperbilirubinemia (total bilirubin ≥10 mg/dl) or by elevated transaminase (alanine transaminase >1,000 IU/liter). Of these patients, 14 underwent MARS treatment (Group M), and 14 were supported with optimal medical treatment without MARS (Group C). Patient characteristics, liver function, and survival were compared between groups. RESULTS: Demographics, clinical risk factors, and pre-ECMO laboratory data were identical between the groups. MARS was used continuously for 8 days ± 9 in Group M. Total bilirubin, alanine transaminase, and international normalized ratio were improved significantly in Group M. There were no MARS-related complications. Survival to wean from ECMO for Group M was 64% (9/14) vs 21% (3/14) for Group C (p = 0.02). Mortality related to worsening liver dysfunction during ECMO was 40% (2/5 deaths) in Group M and 100% (11/11 deaths) in Group C (p = 0.004). The 30-day survival after ECMO was 43% (6/14) in Group M and 14% (2/14) in Group C (p = 0.09). CONCLUSIONS: MARS therapy in patients on ECMO safely accelerated recovery of liver function and improved survival to wean from ECMO, without increasing complications.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Sparks BE, Cavarocchi NC, Hirose H, et al. Extracorporeal membrane oxygenation with multiple-organ failure: Can molecular adsorbent recirculating system therapy improve survival? J Heart Lung Transplant. 2016. PMID: 27863862. doi:10.1016/j.healun.2016.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。